Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Image of Isami J. Salcedo and Sonia Bracegirdle with the PepGen logo

PepGen today announced the appointment of Isami J. Salcedo to Vice President of Program Management and the promotion of Dr Sonia Bracegirdle to the position of Senior Vice President, Strategy & Operations. These new appointments, which follow other key executive appointments announced earlier in 2021, will coordinate the application of PepGen’s technology to a broader spectrum of neuromuscular and neurologic diseases.

 

 

It is my pleasure to announce the promotion of Sonia Bracegirdle to the position of Senior Vice President, Strategy & Operations. Sonia has been a leader of PepGen since 2018, contributing across the organisation in many areas including strategy, IP and licensing efforts, and most recently shepherding our successful $112M Series B financing. As PepGen grows and advances its programmes in Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and beyond, Sonia will lead the team that will support and coordinate these efforts across the company.
- James McArther, PhD, President and Chief Executive Officer of PepGen

Born in New Zealand, Dr Bracegirdle moved to the United Kingdom to undertake her undergraduate studies in Natural Sciences at the University of Cambridge. She then completed a DPhil (PhD) in Organic Chemistry at the University of Oxford. Subsequently, she worked for McKinsey & Company and the Boston Consulting Group in Melbourne and London, respectively, where she was primarily engaged in projects within the pharmaceutical and healthcare sectors. She also worked at Syncona, a biotech venture capital firm, before joining PepGen upon spinout in 2018. Since then, she has been deeply involved in strategy and business operations at PepGen, and in her new role will support the CEO in strategy development and execution.

 

It’s been an honour to play a role in the growth and development of PepGen, and I’m thrilled to be taking on this critical new role to help lead PepGen’s corporate strategy. Since our formation in 2018 we’ve built an exceptional foundation of preclinical data that has established us as a leader in next-generation oligonucleotide therapeutics, and I look forward to continuing to help PepGen achieve our ultimate goal of making a difference in the lives of people and families with rare neuromuscular and neurologic diseases. - Dr Sonia Bracegirdle, Senior Vice President of Strategy and Operations at PepGen

 

 

 

I am also pleased to say that we have appointed Isami Salcedo as Vice President of Program Management. Isami’s deep experience leading program planning at multiple biotechnology companies will help support our goal of delivering transformative therapies for people living with neuromuscular diseases.
- James McArther, PhD, President and Chief Executive Officer of PepGen

Ms Salcedo is an experienced operation and program management professional with a demonstrated successful history of leading initiatives and teams in the biotechnology industry. She has held positions at Proteostasis Therapeutics, a company focused on providing new treatment options for people with cystic fibrosis (now part of Yumanity Therapeutics), and Merck. She has also been a consultant for a number of different start-ups. As part of those roles she has led teams of programme managers and managed rare disease programmes through preclinical, Phase 1, Phase 2, and preparation for Phase 3 studies. In total, she has over 12 years of experience in the pharmaceutical and biotechnology industries. Ms Salcedo earned a Master of Science in Project Management from Boston University and a bachelor’s degree in Marketing from Iberoamerican University in the Dominican Republic.

 

I am excited to join the PepGen team and to be given the opportunity to help advance PepGen’s therapeutic candidates to the clinic. The whole team is hard-working and dedicated, and I am proud to support our mission to progress potentially life-changing therapies for Duchenne muscular dystrophy, myotonic dystrophy and other diseases. - Isami J. Salcedo, Vice President of Program Management at PepGen

Click here to see the original article

Click here to visit PepGen's website